RxDoctor Payments Data

Ryan Mogadam

Medical · Chicopee, MANPI 1558964445

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,171 of the $2,451 with a category attached, or 88.6%. 13 manufacturers reported payments, led by AbbVie at 29.8% of the total. Reporting peaked in 2022 at $1,279 and has fallen 66.8% since, to $425 in 2025.

$2,451in general payments, 2019–2025

Across 111 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$729
  • Novartis$693
  • Johnson & Johnson$473
  • Galderma Laboratories, L.p.$146
  • Sun Pharmaceutical Industries Inc.$119
  • Organon$80
  • plus $212 from 7 others

What the payments were for

  • Food & beverage$2,17189%
  • Education$28011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,451 in reported general payments places this provider in the 85th percentile of 421 medical providers in Massachusetts.

See all medical providers in Massachusetts

Medicare billing

Part B allowed, 2024
$129,623
Medicare patients
541
Services billed
2,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab53$626,407
OtezlaApremilast118$572,462
Skyrizi PenRisankizumab-Rzaa21$446,634
Dupixent PenDupilumab103$377,307
TremfyaGuselkumab20$275,957
Cosentyx Sensoready (2 Pens)Secukinumab17$113,560
Dupixent SyringeDupilumab27$96,508
RinvoqUpadacitinib12$73,798
OpzeluraRuxolitinib Phosphate11$21,476
ZoryveRoflumilast14$14,946
Calcipotriene68$11,547
Betamethasone Dipropionate230$9,865
OraceaDoxycycline Monohydrate11$9,170
Tacrolimus74$8,446
Clobetasol Propionate120$7,244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$473$275,95720 claims
AbbVieRinvoq$729$73,79812 claims
Incyte CorporationOpzelura$22$21,47611 claims
Arcutis Biotherapeutics, Inc.Zoryve$66$14,94614 claims
Galderma Laboratories, L.p.Oracea$146$9,17011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 421 medical providers in Massachusetts.

Other medical in Chicopee

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →